Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Citigroup Upgrades Royalty Pharma to Buy, Announces $50 Price Target

Citigroup analyst Andrew Baum upgrades Royalty Pharma (NASDAQ:RPRX) from Neutral to Buy and announces $50 price target.
byBenzinga Newsdesk
October 29, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Citigroup analyst Andrew Baum upgrades Royalty Pharma (NASDAQ:RPRX) from Neutral to Buy and announces $50 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0